A Biodegradable Polymeric Carrier Based on PEG for Drug Delivery

Abstract

A biodegradable copolymer (PEG-fum), based on poly(ethylene glycol) (PEG) and fumarate (fum) units, was synthesized and studied as a drug carrier. PEG and fum were linked together by ester bonds to confer biodegradability to the polymeric backbone in vivo. Hence, this copolymer can be used with molecular weights above the kidney clearance threshold for PEG without body accumulation. The PEG-fum was designed to be a high drug loading carrier due to the fumarate units, thus, overcoming the limitations of linear PEGs. Suitable reactive groups for drug coupling were added by reacting fumarate with tioglycolic acid (TGA). The pendant TGA carboxylic groups were conjugated to the camptothecin derivative, SN38, taxol, and epirubicin. The SN38 and taxol linked to the PEG-fum-(TGA) increased their solubility 15- and 100-fold, respectively. The rate of SN38 release in plasma was adequate for prolonged circulation n vivoi, while taxol was rapidly hydrolyzed. This relatively fast degradation could hamper the conjugate from accumulating in the tumor tissue by enhanced permeability and retention effect (EPR). Instead, EPR effect could be exploited with the epirubicin conjugate coupled by means of a hydrazone bond. This linkage provides good blood stability, while readily cleaved in acidic environment like those in endosomes and lysosomes. Therefore, the drug is released intercellularly in its active form only after, thus reducing toxic effects.

Keywords

poly(ethylene) glycol biodegradable polymeric carrier prodrugs anticancer-drug EPR effect cell internalization controlled delivery of camptothecin derivative (SN38)taxol and epirubicin.

Get full access to this article

View all access options for this article.

References

Pasut, G. , Guiotto, A. and Veronese, F.M. (2004). Protein, Peptide and Non-peptide Drug PEGylation for Therapeutic Application, Exp. Opin. Ther. Pat., 14(6): 859-894.

Singer, J.W. (2005). Paclitaxel Poliglumex (XYOTAX, CT-2103): a Macromolecular Taxane, J. Contr. Rel., 109(1): 120-126.

Chipman, S.D. , Oldham, F.B. , Pezzoni, G. and Singer, J.W. (2006). Biological and Clinical Characterization of Paclitaxel Poliglumex (PPX, CT-2103), a Macromolecular Polymer-Drug Conjugate, Int. J. Nanomedicine, 1(4): 375-383.

Greco, F. and Vicent, M.J. (2008). Polymer-Drug Conjugates: Current Status and Future Trends, Front. Biosci., 13(7): 2744-2756.

Duncan, R. (2006). Polymer Conjugates as Anticancer Nanomedicines, Nat. Rev. Cancer, 6: 688-701.

Torchilin, V. (2000). Drug Targeting, Eur. J. Pharm. Sci., 11(2): 81-91.

Pasut, G. and Veronese, F.M. (2007). Polymer-drug Conjugation, Recent Achievements and General Strategies, Prog. Polym. Sci., 32(8-9): 933-961.

Yamaoka, T. , Tabata, Y. and Ikada, Y. (1994). Distribution and Tissue Uptake of Poly(ethylene glycol) with Different Molecular Weights after Intravenous Administration to Mice, J. Pharm. Sci., 83(4): 601-606.

Greco, F. , Vicent, M.J. , Gee, S. , Jones, A.T. , Gee, J. , Nicholson, R.I. , et al. (2007). Investigating the Mechanism of Enhanced Cytotoxicity of HPMA Copolymer-Dox-AGM in Breast Cancer Cells, J. Contr. Release, 117(1): 28-39.

10.

Maeda, H. (2001). The Enhanced Permeability and Retention (EPR) Effect in Tumor Vasculature: the Key Role of Tumor-selective Macromolecular Drug Targeting, Adv. Enzyme. Regul., 41(1): 189-207.

11.

Leonelli, F. , La Bella, A. , Migneco, L.M. and Bettolo, R.M. (2008) Design, Synthesis and Applications of Hyaluronic Acid-paclitaxel Bioconjugates, Molecules, 13(2): 360-378.

12.

Guan, H. , McGuire, M.J. , Li, S. and Brown, K.C. (2008) Peptide-targeted Polyglutamic Acid Doxorubicin Conjugates for the Treatment of alpha(v)-beta(6)-Positive Cancers, Bioconj . Chem., 19(9): 1813-1821.

13.

Zhao, H. , Rubio, B. , Sapra, P. , Wu, D. , Reddy, P. , Sai, P. et al. (2008) Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers, Bioconjug. Chem., 19(4): 849-859.

14.

Greenwald, R.B. (2001). PEG Drugs: An Overview , J. Contr. Release, 74(1): 159-171.

15.

Ulbrich, K. , Etrych, T. , Chytil, P. , Pechar, M. , Jelinkova, M. and Rihova, B. (2004). Polymeric Anticancer Drugs with pH-Controlled Activation, Int. J. Pharm., 277(1-2): 63-72.

16.

Ulbrich, K. and Subr, V. (2004). Polymeric Anticancer Drugs with pH-Controlled Activation, Adv. Drug Del. Rev., 56(7): 1023-1050.

17.

Snyder, S.M.L. and Sobocinski, P.Z. (1975). An Improved 2,4,6-Trinitrobenzenesulfonic Acid Method for the Determination of Amines, Analytical Biochem. , 64(1): 284-288.

18.

Andersson, L. , Davies, J. , Duncan, R. , Ferruti, P. , Ford, J. , Kneller, S. et al. (2005). Poly(ethylene glycol)-Poly(ester-carbonate) Block Copolymers Carrying PEG-Peptidyl-Doxorubicin Pendant Side Chains: Synthesis and Evaluation as Anticancer Conjugates, Biomacromolecules, 6(2): 914-926.

19.

Greenwald, R.B. , Gilbert, C.W. , Pendri, A. , Conover, C.D. , Xia, J. and Martinez, A. (1996). Drug Delivery Systems: Water Soluble Taxol 20-Poly(ethylene glycol) Ester Prodrugs-Design and in Vivo Effectiveness, J. Med. Chem., 39(2): 424-431.